Neoprobe introduces updated gamma detection system

Neoprobe, a developer of oncology and cardiovascular surgical and diagnostic products, has introduced its enhanced gamma detection control unit, the Neoprobe gamma detection system (GDS) Model 2300, in connection with its marketing partner, Ethicon Endo-Surgery, a Johnson & Johnson company.

The Dublin, Ohio-based Neoprobe said its GDS control unit contains internal circuitry that allows it to communicate with Neoprobe’s family of wireless probes without the necessity of an external adapter. The company said its wireless gamma detection products are based on Bluetooth technology.

The wireless probes are available with either straight or angled tips and can also be used with all previous models of the company’s neo2000 control unit (Models 2000, 2100 and 2200) using an external serial port adapter, according to the company. Neoprobe said its gamma detection products are used by cancer surgeons in a procedure, called sentinel lymph node biopsy or intraoperative lymphatic mapping.

Around the web

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.